



Horizon Europe

Evaluation Form (HE EIC Accelerator stage 2 – full proposal)

Version 3.0
25 March 2024





SENSITIVE

[INDIVIDUAL EVALUATION REPORT (IER)]
[CONSENSUS REPORT (CR)]
[EVALUATION SUMMARY REPORT]

PROJECT	
Project number:	[project number]
Project name:	[project title]
Project acronym:	[acronym]
Coordinator contact:	[PCoCo name NAME], [organisation]
Call:	[call ID]
Topic:	[topic ID]
Type of action:	[ToA ID]
Responsible service:	[responsible unit, e.g. JUST/04]
Project duration:	[number of months]

PARTICIPANTS					
Number	Role	Short name	Legal name	Country	PIC
1	COO				
2	BEN				
2.1	AE				
3	BEN				
4	AP				

PROJECT ABSTRACT*Text from Proposal Abstract (Application Form Part A).***EVALUATION****Evaluation model:**

[single] [step 1] [step 2]


Panel:

[insert panel identifier]

Evaluators:

[name NAME], [name NAME], [name NAME]

1. EVALUATION

 Applications **must be evaluated as they were submitted**, NOT on their potential if certain changes were made. Therefore, do NOT recommend any modifications (e.g. consortia composition, resources or budget, or inclusion of additional work packages).

 If an application is partly out of scope, this should be reflected in the comments.

1. Excellence

The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:

- Excellence of the company: Does the company have a clear mission and vision and partnerships to realise their ambition to scale up?
- Novelty and breakthrough character of the innovation: Does the innovation have breakthrough character and a high degree of novelty compared to existing solutions, and for EIC Accelerator Challenges, is it addressing the specific objectives of the challenge?
- Timing: Is the timing right for this innovation in terms of users, societal or scientific or technological trends and developments?
- Technological feasibility: has the technology been developed in a safe, secure and reliable manner? Has it been adequately assessed, validated or certified?
- Intellectual Property Strategy: Does your company have the necessary Intellectual Property Rights to ensure freedom to operate and adequate protection of the idea?

Comments:**2. Impact**

The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:

- Competitiveness and demand: Is the innovation better than what the competition proposes, and is the solution bringing sufficient added value to trigger demand from potential customers?
- Market development: Does the innovation have the potential to develop new markets or significantly transform existing ones? Has the potential market for the innovation been adequately quantified, including conditions and growth rates? Is the expected market share acquisition reasonably ambitious and reachable?
- Commercialisation strategy: Is there a convincing and well thought-through strategy for commercialisation, including regulatory approvals/compliance needed, time to market/deployment, and business and revenue model? Are the key partners identified and committed?
- Scale up potential: Does the innovation have the potential to scaleup the company?
For grant only support: can the applicant demonstrate access to the resources needed to commercialise and scale-up the innovation.
- Broader impact: Will the innovation, if successfully commercialised achieve positive broader societal, economic, environmental¹ or climate impacts, and for EIC Challenges does it have the potential to contribute to the expected outcomes and impacts set out in the **Challenge**?

Comments:**3. Level of risk, implementation, and need for Union support**

The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:

- Team: Does the team have the capability and motivation to implement the innovation proposal and bring it to the market? Is there a plan to acquire any critical competencies which are currently missing, including adequate representation of women and men?
- Risk level of the investment (for applicants requesting an investment component): Does the nature and level of risk of the investment in your innovation mean that European market actors are unwilling to commit the full amount that is needed without an investment from the EIC Fund? Is there evidence that market actors would be willing to invest, either alongside the EIC or at a later stage?

Note: if an applicant has previous investors or is in a current investment round, this will not be used as a reason to reject an application against this element. Moreover, this assessment should take into account the international context and whether competitor companies outside of the EU or Associated Countries have access to larger investment amounts.

Note: Small mid-caps will be expected to provide documentary evidence that their bank has refused the financing needed for the project.

- Risk mitigation: Have the main risks (e.g., technological, market, financial, regulatory) been identified, together with measures to take to mitigate them?
- Implementation plan: Is there a clear implementation plan with defined milestones, work packages and deliverables, together with realistic resources and timings?

¹ Projects must comply with the 'do no significant harm' principle enshrined in Article 17 of the EU Taxonomy Regulation as part of the eligibility criteria.

Comments:

2. OTHER QUESTIONS

Opinion on additional questions

Scope of the application

Based on the information provided, this application is:

- ☐ 'in scope' because it corresponds, wholly or in part, to the topic description against which it has been submitted
- ☐ 'out of scope' because:

Use of human embryonic stem cells (hESC)

Does this proposal involve the use of hESC?

- ☐ No
- ☐ Yes

If YES, please state whether the use of hESC is, or is not, in your opinion, necessary to achieve the scientific objectives of the proposal and the reasons why. Alternatively, please state if it cannot be assessed whether the use of hESC is necessary or not, because of a lack of information.

Use of human embryos

Does this proposal involve the use of human embryos?

- ☐ No
- ☐ Yes

If YES, please explain how the human embryos will be used in the project.

Activities excluded from funding

Activities that:

- aim at human cloning for reproductive purposes, or
- intend to modify the genetic heritage of human beings which could make such changes heritable (with the exception of research relating to cancer treatment of the gonads, which may be financed), or
- intend to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer, or
- lead to the destruction of human embryos (for example, for obtaining stem cells)?

are excluded from funding. Does the proposal include any of these activities?

☐

No

☐

Yes

If YES, please explain.

[Comment box]

Do no significant harm principle

Is this proposal compliant with the 'Do no significant harm' principle?

☐

Not applicable

☐

Yes.

☐

Partially

☐

No

☐

Cannot be assessed

If Partially/No/Cannot be assessed please explain.

[Comment box]

Exclusive focus on civil applications

Do the activities proposed have an exclusive focus on civil applications (activities intended to be used in military application or aims to serve military purposes cannot be funded)?

☐

No

☐

Yes

If NO, please explain.

[Comment box]

Artificial Intelligence
<p>Do the activities proposed involve the use and/or development of AI-based systems and/or techniques?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p><i>If YES, the technical robustness of the proposed system must be evaluated under the appropriate criterion.</i></p>

[additional OPTION for CR:

Consensus meeting
Consensus meeting minutes
[Comment box]
Minority opinion
<p>Does this proposal have a minority opinion?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p>If YES, please encode the names of dissenting evaluators and the reasons:</p> <p>[Comment box]</p>

[additional OPTION for ESR (for internal use – will not be included in the ESR sent to applicants):

Panel review
Consensus meeting minutes
[Comment box]
Proposal panel review minutes
[Comment box]

]

HISTORY OF CHANGES		
VERSION	PUBLICATION DATE	CHANGE
1.0	18.06.2021	Initial version (new MFF).
2.0	28.06.2023	Updated criteria in line with the EIC Work Programme 2023
3.0	25.03.2024	Updated criteria for full proposal in line with the EIC Work Programme 2024